Lynx Bio

Lynx Biosciences, Inc. is commercializing a microfluidic platform technology that is leveraging standard-of-care cancer biopsies to measure the response of a patient’s cancer cells in the context of their natural environment. Lynx Biosciences will offer this test as a service to physicians and patients, allowing them to identify them most efficacious treatment option at any stage of the patient’s treatment history. In addition, Lynx Biosciences is actively partnering with pharmaceutical companies to leverage the platform in drug development and clinical trials.

Lynx Bio in the News